drugset / Trial / NCT04121975
CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
This was a prospective, single arm, phase 2 trial. Adult Patients with histologically confirmed locally advanced cervical cancer were enrolled to receive the treatment of concurrent chemoradiotherapy combined with Endostar. The primary endpoint was progression-free survival (PFS) rate at 1 year. The secondary endpoints were PFS, overall survival (OS) and safety.
Timeline
- Start
- 2019-08-01
- Primary completion
- 2021-08
- Completion
- 2022-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 30 mg | — |
| Background | Cisplatin | Other / unclassified | 30 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | — |